Our results reveal a novel combination regimen by using a bioactive compound, GE, and an HDAC inhibitor, TSA, in converting ERα status which may provide a promising therapeutic strategy especially in ERα-negative breast cancer. This evidence concerns the gene HDAC9 and breast carcinoma.